Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients–FINITE study
T Berg, KG Simon, S Mauss, E Schott, R Heyne… - Journal of …, 2017 - Elsevier
Background & Aims There is currently no virological cure for chronic hepatitis B but
successful nucleos (t) ide analogue (NA) therapy can suppress hepatitis B virus (HBV) DNA
replication and, in some cases, result in HBsAg loss. Stopping NA therapy often leads to
viral relapse and therefore life-long therapy is usually required. This study investigated the
potential to discontinue tenofovir disoproxil fumarate (TDF) therapy in HBeAg-negative
patients. Methods Non-cirrhotic HBeAg-negative patients who had received TDF for≥ 4 …
successful nucleos (t) ide analogue (NA) therapy can suppress hepatitis B virus (HBV) DNA
replication and, in some cases, result in HBsAg loss. Stopping NA therapy often leads to
viral relapse and therefore life-long therapy is usually required. This study investigated the
potential to discontinue tenofovir disoproxil fumarate (TDF) therapy in HBeAg-negative
patients. Methods Non-cirrhotic HBeAg-negative patients who had received TDF for≥ 4 …